Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will
be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but
not both.